Next Article in Journal
Whole Genome Sequencing Results Associated with Minimum Inhibitory Concentrations of 14 Anti-Tuberculosis Drugs among Rifampicin-Resistant Isolates of Mycobacterium Tuberculosis from Iran
Previous Article in Journal
Estimation of the Transmission Risk of the 2019-nCoV and Its Implication for Public Health Interventions
Open AccessArticle

Body Weight as a Determining Factor in the Predominance of Adverse Drug Reactions Induced by Fixed-Dose Adalimumab Injections in Female Patients in a Korean Hospital Setting

1
Department of Pharmacy, Seoul National University Hospital, Seoul 03080, Korea
2
College of Pharmacy, Dongguk University Seoul, Goyang-si, Gyeonggi-do 10326, Korea
3
Duksung Innovative Drug Center, College of Pharmacy, Duksung Women’s University, Seoul 01369, Korea
4
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(2), 461; https://doi.org/10.3390/jcm9020461
Received: 10 January 2020 / Revised: 31 January 2020 / Accepted: 3 February 2020 / Published: 7 February 2020
(This article belongs to the Section Pharmacology)
Adalimumab is used at 40-mg dose to treat systemic inflammatory diseases. Given the impact of adverse drug reactions (ADRs), which particularly result in the discontinuation of adalimumab therapy in female patients, this study examined whether sex affects the frequency and type of ADRs induced by adalimumab. In this study, the prescription records and laboratory data of patients aged ≥19 years who had been admitted to the Seoul National University Hospital (SNUH) and prescribed adalimumab were analyzed using an electronic medical record database. The analysis revealed that female patients more frequently experienced adalimumab-induced ADRs compared with male patients (63.2% vs. 52.2%). The incidence of ADRs was significantly higher in female patients with ankylosing spondylitis or rheumatoid arthritis than in male patients with similar conditions (81.5% vs. 60.7% or 64.4% vs. 50.0%, respectively). The median body weight (BW) was lower in female patients than in male patients (54.0 vs. 66.0 kg). Moreover, the incidence of ADRs in patients with a BW of <54.0 kg (i.e., the median female BW) was higher than for those with a BW of ≥54.0 kg, in both males and females. Our results suggested that the predominance of ADRs induced by adalimumab in females was because of their relatively lower BW. This suggests the importance of BW as a determining factor in sex disparity of ADR occurrences. View Full-Text
Keywords: adalimumab; adverse drug reaction; gender; body weight; skin; infection; test abnormality adalimumab; adverse drug reaction; gender; body weight; skin; infection; test abnormality
Show Figures

Figure 1

MDPI and ACS Style

Kim, K.S.; Choi, Y.H.; Moon, A.; Kim, S.G. Body Weight as a Determining Factor in the Predominance of Adverse Drug Reactions Induced by Fixed-Dose Adalimumab Injections in Female Patients in a Korean Hospital Setting. J. Clin. Med. 2020, 9, 461. https://doi.org/10.3390/jcm9020461

AMA Style

Kim KS, Choi YH, Moon A, Kim SG. Body Weight as a Determining Factor in the Predominance of Adverse Drug Reactions Induced by Fixed-Dose Adalimumab Injections in Female Patients in a Korean Hospital Setting. Journal of Clinical Medicine. 2020; 9(2):461. https://doi.org/10.3390/jcm9020461

Chicago/Turabian Style

Kim, Kwi S.; Choi, Young H.; Moon, Aree; Kim, Sang G. 2020. "Body Weight as a Determining Factor in the Predominance of Adverse Drug Reactions Induced by Fixed-Dose Adalimumab Injections in Female Patients in a Korean Hospital Setting" J. Clin. Med. 9, no. 2: 461. https://doi.org/10.3390/jcm9020461

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop